Physiostim
Private Company
Funding information not available
Overview
PhysioStim is a specialized preclinical CRO offering expert cardiovascular testing services, including mandatory cardiac safety assays (e.g., hERG-GLP) and innovative human translational platforms using human vascular tissues and stem cell-derived cardiomyocytes. The company serves over 200 international biotech and pharma clients, combining deep scientific expertise with GLP-certified operations to de-risk drug development. Its business model is entirely service-based, positioning it as a critical partner for companies navigating complex cardiovascular safety and efficacy requirements.
Technology Platform
Specialized preclinical CRO platform combining GLP-certified cardiac safety assays (hERG, ion channels, Langendorff) with a human translational platform. This includes a vasoreactivity platform using human vascular tissues from healthy/diseased donors and a human cardiomyocyte platform using hiPSC-derived cells for integrative cardiotoxicity and efficacy assessment.
Opportunities
Risk Factors
Competitive Landscape
PhysioStim competes with large, full-service global CROs (e.g., Charles River, Labcorp) that offer cardiovascular safety packages, and with other niche, specialty CROs focused on cardiac or electrophysiology services. Its competitive differentiation lies in its deep specialization, GLP heritage, and proprietary access to human translational models, which may not be as developed in larger, more generalized competitors.